YI 📈 111 - Overview
Exchange: NASDAQ • Country: China • Currency: USD • Type: Common Stock • ISIN: US68247Q1022
YI: Medicines, Supplements, Contact Lenses, Medical Devices, Personal Care Products
111, Inc., together with its subsidiaries, operates an integrated online and offline platform in the healthcare market in the People's Republic of China. It operates in two segments, B2C and B2B. The company sells medical and wellness products through online retail, and wholesale and retail pharmacies, as well as provides value-added services that include online consultation services and electronic prescription services to consumers. It offers prescription and over-the counter drugs, including western and traditional Chinese medicines; nutritional supplements, such as vitamins and dietary products; contact lenses; medical supplies and devices comprising bandages and thermometers; and personal care products consisting of skin care, birth control, sexual wellness products, and baby products. The company also operates an online marketplace where third-party sellers can directly sell to pharmacies; provides online loan application services to the clients of 1 Pharmacy, which include pharmacies and wholesalers; and data and supply chain integration services. In addition, it offers warehousing, logistics, procurement, research and development, and consulting services; and software development and information technology support services. The company operates offline retail pharmacies under the Yi Hao Pharmacy brand name in Guangdong, Guangzhou, Tianjin, and Kunshan. It serves pharmacies, pharmaceutical companies, medical professionals, and insurance companies. The company was formerly known as New Peak Group and changed its name to 111, Inc. in April 2018. 111, Inc. was founded in 2010 and is headquartered in Shanghai, the People's Republic of China. Web URL: https://corporate.111.com.cn
Additional Sources for YI Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
YI Stock Overview
Market Cap in USD | 52m |
Sector | Healthcare |
Industry | Medical Distribution |
GiC Sub-Industry | Drug Retail |
IPO / Inception | 2018-09-12 |
YI Stock Ratings
Growth 5y | -90.9% |
Fundamental | 29.3% |
Dividend | - |
Rel. Strength Industry | -471 |
Analysts | - |
Fair Price Momentum | 0.56 USD |
Fair Price DCF | 210.88 USD |
YI Dividends
No Dividends PaidYI Growth Ratios
Growth Correlation 3m | -16.4% |
Growth Correlation 12m | -88.4% |
Growth Correlation 5y | -88.4% |
CAGR 5y | -29.71% |
CAGR/Mean DD 5y | -0.42 |
Sharpe Ratio 12m | -0.15 |
Alpha | -64.44 |
Beta | 0.94 |
Volatility | 87.43% |
Current Volume | 183.7k |
Average Volume 20d | 184.3k |
What is the price of YI stocks?
As of December 22, 2024, the stock is trading at USD 0.88 with a total of 183,700 shares traded.
Over the past week, the price has changed by -3.85%, over one month by +20.97%, over three months by +20.97% and over the past year by -50.33%.
As of December 22, 2024, the stock is trading at USD 0.88 with a total of 183,700 shares traded.
Over the past week, the price has changed by -3.85%, over one month by +20.97%, over three months by +20.97% and over the past year by -50.33%.
Is 111 a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, 111 is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 29.30 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of YI as of December 2024 is 0.56. This means that YI is currently overvalued and has a potential downside of -36.36%.
Neither. Based on ValueRay Fundamental Analyses, 111 is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 29.30 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of YI as of December 2024 is 0.56. This means that YI is currently overvalued and has a potential downside of -36.36%.
Is YI a buy, sell or hold?
111 has no consensus analysts rating.
111 has no consensus analysts rating.
What are the forecast for YI stock price target?
According to ValueRays Forecast Model, YI 111 will be worth about 0.6 in December 2025. The stock is currently trading at 0.88. This means that the stock has a potential downside of -29.55%.
According to ValueRays Forecast Model, YI 111 will be worth about 0.6 in December 2025. The stock is currently trading at 0.88. This means that the stock has a potential downside of -29.55%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 6 | 577.3% |
Analysts Target Price | 6 | 577.3% |
ValueRay Target Price | 0.6 | -29.5% |